The Demuris proprietary toolbox allows us to rapidly identify leads, and combines our synthetic biology capabilities to optimize these compounds for optimal therapeutic benefit.
Funding the development of new antibiotics for MDR Gram negative infections Newcastle, UK – December 16, 2020 – Demuris Limited a company focused on the
£800,000 grant for optimization of novel antibiotics targeting multidrug-resistant tuberculosis. Newcastle, UK – September 11, 2019 – Demuris Limited, a company focused on the discovery and
Focused on the development of novel therapeutics for mitochondrial diseases. Newcastle, UK – 2 August 2019 – The Wellcome Centre for Mitochondrial Research (WCMR) at Newcastle